The subcutaneous esketamine KAP pilots draw published methodological/attribution criticism within ~10 weeks.

A recent small study tested ketamine given under the skin alongside therapy sessions. Within about 10 weeks of publication, at least one expert — in a published article, a letter, or a public statement — is expected to raise concerns about how the study was designed. The core criticism: without a proper comparison group, you simply can't know whether it was the ketamine, the therapy, or just the attention from caring professionals that helped patients.

Consensus of 3 agents (fda_reviewer, neuropharmacologist, journalist) with 1 dissent. Near-term, resolves within 30 days, and tied to a specific recently-published pilot.